Pharming Group N.V.
ISIN: NL0010391025 | Ticker: PHARM | LEI: 724500DCJ9MPG74JEH91
Country: Netherlands
Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Our key strengths include the following:
- Sales growth of our commercialized asset.
- Proven rare-disease commercialization capabilities.
- Internal pipeline of product candidates.
- Transgenic Production Platform Technology.
- Data exclusivity, know-how and intellectual property.
1988
Served areaWorldwide
HeadquartersDarwinweg 24, 2333 Leiden, Zuid-Holland – Netherlands
| Line item in (usd) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | 255,915,000.00 | 418,453,000.00 | 397,315,000.00 | 425,797,000.00 |
| Noncurrent Assets | 136,479,000.00 | 155,241,000.00 | 147,871,000.00 | 148,297,000.00 |
| Property Plant And Equipment | 9,591,000.00 | 12,226,000.00 | 13,222,000.00 | 10,392,000.00 |
| Intangible Assets Other Than Goodwill | 79,403,000.00 | 94,083,000.00 | 83,834,000.00 | 75,121,000.00 |
| Investment Accounted For Using Equity Method | 6,177,000.00 | 7,118,000.00 | 7,201,000.00 | 2,501,000.00 |
| Noncurrent Prepayments | 0.00 | 0.00 | 194,000.00 | 228,000.00 |
| Deferred Tax Assets | 32,061,000.00 | 31,877,000.00 | 21,216,000.00 | 22,973,000.00 |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | N/A | N/A | 0.00 | 6,827,000.00 |
| Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | 0.00 | 0.00 | 1,449,000.00 | 403,000.00 |
| Noncurrent Restricted Cash And Cash Equivalents | 2,543,000.00 | 510,000.00 | 812,000.00 | 1,099,000.00 |
| Current Assets | 119,435,000.00 | 263,212,000.00 | 249,444,000.00 | 277,500,000.00 |
| Inventories | 16,223,000.00 | 21,157,000.00 | 27,310,000.00 | 42,326,000.00 |
| Trade And Other Current Receivables | 28,864,000.00 | 35,901,000.00 | 29,983,000.00 | 27,619,000.00 |
| Cash and cash equivalents | 74,348,000.00 | 205,159,000.00 | 191,924,000.00 | 207,342,000.00 |
| Current Restricted Cash And Cash Equivalents | 0.00 | 995,000.00 | 227,000.00 | 213,000.00 |
| Equity And Liabilities | 255,915,000.00 | 418,453,000.00 | 397,315,000.00 | 425,797,000.00 |
| Equity | 117,388,000.00 | 183,435,000.00 | 192,916,000.00 | 204,638,000.00 |
| Issued Capital | 7,226,000.00 | 7,312,000.00 | 7,429,000.00 | 7,509,000.00 |
| Retained Earnings | -340,715,000.00 | -295,621,000.00 | -273,167,000.00 | -256,431,000.00 |
| Share Premium | 441,951,000.00 | 447,130,000.00 | 455,254,000.00 | 462,297,000.00 |
| Other Reserves | 8,926,000.00 | 24,614,000.00 | 3,400,000.00 | -8,737,000.00 |
| Noncurrent Liabilities | 24,273,000.00 | 158,169,000.00 | 157,628,000.00 | 161,461,000.00 |
| Other Noncurrent Financial Liabilities | 19,380,000.00 | 212,000.00 | 165,000.00 | 0.00 |
| Noncurrent Portion Of Noncurrent Bonds Issued | 0.00 | 149,727,000.00 | 139,007,000.00 | 131,618,000.00 |
| Current Liabilities | 114,254,000.00 | 76,849,000.00 | 46,771,000.00 | 59,698,000.00 |
| Trade And Other Current Payables | 40,646,000.00 | 47,666,000.00 | 42,473,000.00 | 54,465,000.00 |
| Other Current Financial Liabilities | 20,000,000.00 | 25,000,000.00 | 0.00 | N/A |
| Current Derivative Financial Liabilities | 301,000.00 | 181,000.00 | 0.00 | N/A |
| Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued | 0.00 | 2,040,000.00 | 1,879,000.00 | 1,768,000.00 |
| Line item in (usd) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 212,174,000.00 | 198,871,000.00 | 205,622,000.00 |
| Other Income | 1,829,000.00 | 2,620,000.00 | 14,523,000.00 |
| Profit Loss From Operating Activities | 76,256,000.00 | 13,561,000.00 | 18,233,000.00 |
| Finance Income | 715,000.00 | 14,894,000.00 | 4,485,000.00 |
| Finance Costs | 33,308,000.00 | 6,185,000.00 | 5,463,000.00 |
| Profit Loss Before Tax | 44,094,000.00 | 23,078,000.00 | 14,987,000.00 |
| Income Tax Expense Continuing Operations | 6,348,000.00 | 7,082,000.00 | 1,313,000.00 |
| Profit (loss) | 37,746,000.00 | 15,996,000.00 | 13,674,000.00 |
| Line item in (usd) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 37,746,000.00 | 15,996,000.00 | 13,674,000.00 |
| Adjustments For Finance Costs | N/A | 33,308,000.00 | 6,196,000.00 | 5,463,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -4,934,000.00 | -6,153,000.00 | -15,016,000.00 |
| Adjustments For Sharebased Payments | N/A | 6,537,000.00 | 9,056,000.00 | 6,392,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | -69,000.00 | -114,000.00 | 1,185,000.00 |
| Adjustments For Undistributed Profits Of Associates | N/A | 362,000.00 | 694,000.00 | -1,083,000.00 |
| Other Adjustments For Noncash Items | N/A | -1,624,000.00 | 524,000.00 | -1,576,000.00 |
| Interest Received Classified As Operating Activities | N/A | 715,000.00 | 53,000.00 | 85,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 2,658,000.00 | 0.00 | 1,235,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 83,626,000.00 | 37,842,000.00 | 22,458,000.00 |
| Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities | N/A | 0.00 | 4,589,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 4,657,000.00 | 10,739,000.00 | 1,376,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 9,060,000.00 | 3,447,000.00 | 601,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -15,629,000.00 | -21,305,000.00 | 5,323,000.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | 2,791,000.00 | 4,718,000.00 | 2,281,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 57,231,000.00 | 0.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 2,186,000.00 | 3,217,000.00 | 3,311,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 2,142,000.00 | 4,448,000.00 | 3,952,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 60,686,000.00 | -27,947,000.00 | -4,982,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 128,683,000.00 | -11,410,000.00 | 22,799,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 2,128,000.00 | -1,825,000.00 | -7,381,000.00 |
| Cash and cash equivalents | 74,348,000.00 | 205,159,000.00 | 191,924,000.00 | 207,342,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 24.05.23 | D.A. Jorn | Non-Executive member | Other | EUR 0.00 |
| 21.03.23 | P. Sekhri | Non-Executive member | Other | EUR 0.00 |
| 27.10.22 | P. Sekhri | Non-Executive member | Buy | EUR 12,232.22 |
| 27.10.22 | M. Pykett | Non-Executive member | Buy | EUR 9,174.40 |
| 04.08.22 | P. Sekhri | Non-Executive member | Buy | EUR 10,000.23 |
| 04.08.22 | S. Baert | Non-Executive member | Buy | EUR 7,500.36 |
| 25.05.22 | J. van der Meijs | Non-Executive member | Buy | EUR 86,490,000.00 |
| 25.05.22 | P. Sekhri | Non-Executive member | Buy | EUR 9,527.62 |
| 25.05.22 | M. Pykett | Non-Executive member | Buy | EUR 7,146.86 |
| 24.03.22 | S. de Vries | Non-Executive member | Buy | EUR 232,249.50 |
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Millennium International Management LP | 0.51% | 15.01.24 |
| Highbridge Capital Management LLC | 0.94% | 18.04.24 |
| Arrowstreet Capital, Limited Partnership | 0.51% | 21.11.23 |
| Citadel Advisors LLC | 0.50% | 13.02.24 |
| Citadel Securities (Europe) Limited | 0.50% | 16.04.24 |
| Marshall Wace LLP | 0.50% | 22.08.23 |
| Total | 3.46% |
NL0010391025
LEI724500DCJ9MPG74JEH91
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.